Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy

Radiotherapy and Oncology

Volumn 82, Issue 1, 2007, Pages 10-17

  Bussink, Johan ^a   Kaanders, Johannes H A M ^a   van der Kogel, Albert J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

EGFR; Hypoxia; Radiotherapy; VEGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PIMONIDAZOLE; PROTEIN KINASE B; RAS PROTEIN; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; CANCER RADIOTHERAPY; CELL CYCLE REGULATION; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITION; EVALUATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IONIZING RADIATION; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RESISTANCE; TUMOR VASCULARIZATION;

CELL CYCLE; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33846201705     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2006.10.022     Document Type: Review

References (88)

1. Akakura N., Kobayashi M., Horiuchi I., et al. Constitutive expression of hypoxia-inducible factor-1{alpha} renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61 (2001) 6548-6554
2. Allalunis-Turner M.J., Franko A.J., and Parliament M.B. Modulation of oxygen consumption rate and vascular endothelial growth factor mRNA expression in human malignant glioma cells by hypoxia. Br J Cancer 80 (1999) 104-109
3. Ang K.K., Berkey B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (2002) 7350-7356
4. Arsham A.M., Plas D.R., Thompson C.B., and Simon M.C. Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis. Cancer Res 64 (2004) 3500-3507
5. Arteel G.E., Thurman R.G., Yates J.M., and Raleigh J.A. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer 72 (1995) 889-895
6. Bentzen S.M., Atasoy B.M., Daley F.M., et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23 (2005) 5560-5567
7. Bernsen H.J., Rijken P.F., Peters J.P., et al. Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. J Neurooncol 44 (1999) 129-136
8. Blancher C., Moore J.W., Robertson N., and Harris A.L. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 61 (2001) 7349-7355
9. Bonner J.A., Raisch K.P., Trummell H.Q., et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 18 (2000) 47S-53S
10. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
11. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., and Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 (1997) 285-289
12. Bussink J., Kaanders J.H., Rijken P.F., et al. Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide. Radiother Oncol 50 (1999) 173-184
13. Bussink J., Kaanders J.H.A.M., and van der Kogel A.J. Tumor hypoxia at the micro regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 67 (2003) 3-15
14. Cao Y., Li C.-Y., Moeller B.J., et al. Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res 65 (2005) 5498-5505
15. Carmeliet P., Dor Y., Herbert J.M., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
16. Dewhirst M.W. Concepts of oxygen transport at the microcirculatory level. Semin Radiat Oncol 8 (1998) 143-150
17. 2 gradients in window chamber tumours: impact on tumour hypoxia. Br J Cancer 79 (1999) 1717-1722
18. Dittmann K., Mayer C., and Rodemann H.P. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76 (2005) 157-161
19. Downward J., Parker P., and Waterfield M.D. Autophosphorylation sites on the epidermal growth factor receptor. Nature 311 (1984) 483-485
20. Durand R.E., and Aquino-Parsons C. The fate of hypoxic (pimonidazole-labelled) cells in human cervix tumours undergoing chemo-radiotherapy. Radiother Oncol 80 (2006) 138-142
21. Eicheler W., Krause M., Hessel F., Zips D., and Baumann M. Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. Radiother Oncol 76 (2005) 151-156
22. Elton T.S., Oparil S., Taylor G.R., et al. Normobaric hypoxia stimulates endothelin-1 gene expression in the rat. Am J Physiol 263 (1992) R1260-R1264
23. Eriksen J.G., Steiniche T., Overgaard J., and Danish Head and Neck Cancer study group (DAHANCA). The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol 74 (2005) 93-100
24. Etienne M.C., Pivot X., Formento J.L., et al. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 79 (1999) 1864-1869
25. Evans S.M., Hahn S., Pook D.R., et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 60 (2000) 2018-2024
26. Evans S.M., Fraker D., Hahn S.M., et al. EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 64 (2006) 922-927
27. Fenton B.M., Paoni S.F., and Ding I. Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. Radiother Oncol 72 (2004) 221-230
28. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 69 (2005) 11-16
29. Folkman J. Incipient angiogenesis. J Natl Cancer Inst 92 (2000) 94-95
30. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 (1996) 4604-4613
31. Fukumura D., Xu L., Chen Y., Gohongi T., Seed B., and Jain R.K. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 61 (2001) 6020-6024
32. Gee M.S., Procopio W.N., Makonnen S., Feldman M.D., Yeilding N.M., and Lee W.M.F. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 162 (2003) 183-193
33. Giatromanolaki A., Koukourakis M.I., Sivridis E., et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61 (2001) 7992-7998
34. Gleadle J.M., and Ratcliffe P.J. Hypoxia and the regulation of gene expression. Mol Med Today 4 (1998) 122-129
35. Granville C.A., Memmott R.M., Gills J.J., and Dennis P.A. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 12 (2006) 679-689
36. Harari P.M., and Huang S.M. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 11 (2001) 281-289
37. Herbst R.S. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59 (2004) 21-26
38. Höckel M., Schlenger K., Aral B., Mitze M., Schaffer U., and Vaupel P. Association between tumor hypoxia and malignant progression in advanced carcinoma of the uterine cervix. Cancer Res 56 (1996) 4509-4515
39. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 (2005) 341-354
40. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res 48 (1988) 2641-3658
41. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
42. Kaanders J.H., Wijffels K.I., Marres H.A., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62 (2002) 7066-7074
43. Kennedy A.S., Raleigh J.A., Perez G.M., et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys 37 (1997) 897-905
44. Kim D.W., Huamani J., Fu A., and Hallahan D.E. Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. Int J Radiat Oncol Biol Phys 64 (2006) 38-46
45. Kim I.A., Fernandes A.T., Gupta A.K., McKenna W.G., and Bernhard E.J. The influence of Ras pathway signaling on tumor radiosensitivity. Cancer Metastasis Rev 23 (2004) 227-236
46. Kirsch M., Schackert G., and Black P.M. Anti-angiogenic treatment strategies for malignant brain tumors. J Neurooncol 50 (2000) 149-163
47. Koch C.E., Evans S.M., and Lord E.M. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-2-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 72 (1995) 869-874
48. Konerding M.A., Malkusch W., Klapthor B., et al. Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br J Cancer 80 (1999) 724-732
49. Koritzinsky M., Magagnin M.G., van den Beucken T., et al. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J 25 (2006) 1114-1125
50. Koumenis C. ER stress, hypoxia tolerance and tumor progression. Curr Mol Med 6 (2006) 55-69
51. Koumenis C., and Wouters B.G. "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. Mol Cancer Res 4 (2006) 423-436
52. Kowanetz M., and Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12 (2006) 5018-5022
53. Krause M., Ostermann G., Petersen C., et al. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 76 (2005) 162-167
54. Lal A., Peters H., St Croix B., et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93 (2001) 1337-1343
55. Li C.Y., Shan S., Huang Q., et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92 (2000) 143-147
56. Ljungkvist A.S., Bussink J., Kaanders J.H., et al. Hypoxic cell turnover in different solid tumor lines. Int J Radiat Oncol Biol Phys 62 (2005) 1157-1168
57. Ljungkvist A.S.E., Bussink J., Kaanders J.H.A.M., Wiedenmann N.E., Vlasman R., and van der Kogel A.J. Dynamics of hypoxia, proliferation and apoptosis after irradiation in a murine tumor model. Radiat Res 165 (2006) 326-336
58. Ljungkvist ASE, Bussink J, Kaanders JHAM, van der Kogel AJ. Dynamics of hypoxia measured with bioreductive hypoxic cell markers. Radiat Res, in press.
59. Mazure N.M., Chen E.Y., Laderoute K.R., and Giaccia A.J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90 (1997) 3322-3331
60. Mizukami Y., Li J., Zhang X., Zimmer M.A., Iliopoulos O., and Chung D.C. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 64 (2004) 1765-1772
61. Moeller B.J., Cao Y., Vujaskovic Z., Li C.Y., Haroon Z.A., and Dewhirst M.W. The relationship between hypoxia and angiogenesis. Semin Radiat Oncol 14 (2004) 215-221
62. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005) 18-24
63. Nordsmark M., Loncaster J., Aquino-Parsons C., et al. The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol 80 (2006) 123-131
64. Ord J.J., Streeter E., Jones A., et al. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. Br J Cancer 92 (2005) 2140-2147
65. Rakugi H., Tabuchi Y., Nakamaru M., et al. Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia. Biochem Biophys Res Commun 169 (1990) 973-977
66. Raleigh J.A., Miller G.G., Franko A.J., Koch C.J., Fuciarelli A.F., and Kelly D.A. Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. Br J Cancer 56 (1987) 395-400
67. Raleigh J.A., Chou S.C., Arteel G.E., and Horsman M.R. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 151 (1999) 580-589
68. Ravi R., Mookerjee B., Bhujwalla Z.M., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14 (2000) 34-44
69. Robert F., Ezekiel M.P., Spencer S.A., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19 (2001) 3234-3243
70. Russell J.S., Raju U., Gumin G.J., et al. Inhibition of radiation-induced nuclear factor-kappaB activation by an anti-Ras single-chain antibody fragment: lack of involvement in radiosensitization. Cancer Res 62 (2002) 2318-2326
71. Schuuring J., Bussink J., Bernsen H.J., Peeters W., and van Der Kogel A.J. Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line. Int J Radiat Oncol Biol Phys 61 (2005) 529-534
72. Semenza G.L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88 (2000) 1474-1480
73. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64 (2002) 993-998
74. Shweiki D., Itin A., Soffer D., and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359 (1992) 843-845
75. Smith T.A. Facilitative glucose transporter expression in human cancer tissue. Br J Biomed Sci 56 (1999) 285-292
76. Sobel A.T., Branellec A.I., Blanc C.J., and Lagrue G.A. Physicochemical characterization of a vascular permeability factor produced by con A-stimulated human lymphocytes. J Immunol 119 (1977) 1230-1234
77. Solomon B., Binns D., Roselt P., et al. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol Cancer Ther 4 (2005) 1417-1422
78. Toulany M., Kasten-Pisula U., Brammer I., et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 12 (2006) 4119-4126
79. Toulany M., Dittmann K., Kruger M., Baumann M., and Rodemann H.P. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother Oncol 76 (2005) 143-150
80. Troost E.G., Bussink J., Kaanders J.H.A.M., et al. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol 76 (2005) 194-199
81. 2 tension measurements. Cancer Res 51 (1991) 3316-3322
82. Vukovic V., Haugland H.K., Nicklee T., Morrison A.J., and Hedley D.W. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 61 (2001) 7394-7398
83. Walenta S., Snyder S., Haroon Z.A., et al. Tissue gradients of energy metabolites mirror oxygen tension gradients in a rat mammary carcinoma model. Int J Radiat Oncol Biol Phys 51 (2001) 840-848
84. Warburton C., Dragowska W.H., Gelmon K., et al. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 10 (2004) 2512-2524
85. Willam C., Masson N., Tian Y.M., et al. Peptide blockade of HIFalpha degradation modulates cellular metabolism and angiogenesis. Proc Natl Acad Sci USA 99 (2002) 10423-10428
86. Winkler F., Kozin S.V., Tong R.T., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563
87. Withers H.R., Taylor J.M., and Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27 (1988) 131-146
88. Wykoff C.C., Beasley N.J.P., Watson P.H., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60 (2000) 7075-7083